Navigation Links
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
Date:11/11/2013

eading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional clinical-stage cannabinoid product candidates targeting epilepsy (including an orphan pediatric epilepsy program), Type 2 diabetes, ulcerative colitis, glioma and schizophrenia. For further information, please visit www.gwpharm.com.

Forward-looking statements

This news release may contain forward-looking statements that reflect GWs current expectations regarding future events, including statements regarding our clinical goals, our plans for a clinical trial, the ability to conduct clinical trials sufficient to achieve positive completion, and the therapeutic and commercial value of the company's compounds. To the degree we are able to conduct clinical trials, we may have difficulty in enrolling candidates for testing and we may not be able to achieve the desired results. Forward-looking statements involve risks and uncertainties.  Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the GW's research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex® and other products by consumer and medical professionals. A further list and description of risks, uncertainties and other risks associated with an investment in GW can be found in GW's filings with the U.S. Securities and Exchange Commission, including the prospectus related to the NASDAQ offering filed by GW with the SEC on May 1, 2013. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result o
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 This report is a ... industry. For an overview analysis, the report introduces ... chain structure, industry overview, policy analysis, and news ... has witnessed rapid development with key manufacturers ... This report mentions quartz tubing upstream raw materials ...
(Date:12/17/2014)... SPRING, Md. , Dec. 17, 2014  United ... two senior executive promotions as well as changes to ... Senior Executive Promotions United Therapeutics ... to President and Co-Chief Executive Officer and David ... Operating Officer.  In connection with these promotions, Dr. Rothblatt,s ...
(Date:12/15/2014)... YORK & PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI ), a leading developer ... today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was ... Israel,s Office of the Chief Scientist ... been in receipt of grant support from the Office ...
(Date:12/13/2014)... 13, 2014 CanDiag, Inc., a University ... has changed its name to OncoTab, Inc. , ... where we are today,” said CEO and Chief Science ... applications beyond breast cancer diagnostics to include imaging and ... that evolution.” , Founded in 2011 by Dr. Mukherjee, ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2
... 20, 2011 Scientists Drs. Samuel and Elenore Bogoch of ... increase in Replikin Counts of the EHEC lethal strains of ... strains of E. Coli have been studied in laboratories in ... available in the public databases. Replikins are subsequences of the ...
...   Hospitals, health systems to ... Sigma and other,performance management solutions ... information products,and services, has struck an exclusive partnership with ... online learning solutions for process,improvement. Elsevier will ...
... has the potential to make consumer electronic devices faster ... scale of electronics, also make graphene difficult to fabricate ... In September 2010, a UCLA research team reported ... were able to fabricate graphene transistors with unparalleled speed. ...
Cached Biology Technology:Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 3Elsevier Strikes Exclusive eLearning Partnership with The Quality Group 2Elsevier Strikes Exclusive eLearning Partnership with The Quality Group 3Elsevier Strikes Exclusive eLearning Partnership with The Quality Group 4UCLA team reports scalable fabrication of self-aligned graphene transistors, circuits 2
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a ... that its U.are.U ® fingerprint readers have been ... in Central Mexico . The bakery ... to eliminate payroll issues caused by employees clocking in ... the U.are.U fingerprint readers, Montparnasse relied on paper timecards ...
(Date:11/10/2014)... U.S. store shelves in early 2010, and people have ... packets can be tossed into a washing machine without ... The convenience, though, has come with risks for young ... Children,s Hospital found that from 2012 through 2013, U.S. ... than 6 years of age swallowing, inhaling, or otherwise ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Study finds laundry detergent pods, serious poisoning risk for children 2
... Jan. 7, 2013 Halting climate change will require "a ... eradicate harmful carbon dioxide emissions, not just stabilize them, according ... In a Jan. 9 paper in Environmental Research Letters ... take a fresh look at the popular "wedge" approach to ...
... from Italy and their offspring form one of the largest ... their state of health and risk of mortality. In a ... University of Zurich,s Institute of Social and Preventative Medicine calculated ... Immigrants from Italy live longer than ...
... New research led by the Karolinska Institutet, Sweden and the ... human gene and the composition of human gastrointestinal bacteria. In ... Gut , the team outline new evidence suggesting that the ... of the billions of microbes in the human gastrointestinal tract ...
Cached Biology News:Major cuts to surging CO2 emissions are needed now, not down the road, study finds 2Italian immigrants live longer 2International study suggests human genes influence gut microbial composition 2
Agarose, pulse field, 100 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Request Info...
Recombinant Rat Leptin, Ultra Pure...
Biology Products: